Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Subscribe To Our Newsletter & Stay Updated
